New drug cocktail aims to halt sarcoma progression
NCT ID NCT07457775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—liposomal irinotecan, temozolomide, and bevacizumab—in 24 people with soft tissue sarcoma that has returned or not responded to prior treatment. The goal is to see if the combination can slow or stop tumor growth. Participants will receive the drugs intravenously in 3-week cycles, and the study will track how long they live without the disease worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal irinotecan, temozolomide, and bevacizumab
- What this could lead to
- If successful, this could offer a new treatment option for people with soft tissue sarcoma that has come back or stopped responding to other therapies.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The drug combination may cause side effects and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (EXCLUDING GIST) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
2nd Affiliated Hospital, School of Medicine
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.